info:eu-repo/semantics/article
Metformin and propranolol combination prevents cancer progression and metastasis in different breast cancer models
Fecha
2017-01Registro en:
Rico, Maria Jose; Baglioni, María Virginia; Bondarenko, Maryna; Laluce, Nahuel Cesatti; Rozados, Viviana Rosa; et al.; Metformin and propranolol combination prevents cancer progression and metastasis in different breast cancer models; Impact Journals LLC; Oncotarget; 8; 2; 1-2017; 2874-2889
1949-2553
CONICET Digital
CONICET
Autor
Rico, Maria Jose
Baglioni, María Virginia
Bondarenko, Maryna
Laluce, Nahuel Cesatti
Rozados, Viviana Rosa
André, Nicolas
Carré, Manon
Scharovsky, Olga Graciela
Menacho Márquez, Mauricio Ariel
Resumen
Discovery of new drugs for cancer treatment is an expensive and time-consuming process and the percentage of drugs reaching the clinic remains quite low. Drug repositioning refers to the identification and development of new uses for existing drugs and represents an alternative drug development strategy. In this work, we evaluated the antitumor effect of metronomic treatment with a combination of two repositioned drugs, metformin and propranolol, in triple negative breast cancer models. By in vitro studies with five different breast cancer derived cells, we observed that combined treatment decreased proliferation (P < 0.001), mitochondrial activity (P < 0.001), migration (P < 0.001) and invasion (P < 0.001). In vivo studies in immunocompetent mice confirmed the potential of this combination in reducing tumor growth (P < 0.001) and preventing metastasis (P < 0.05). Taken together our results suggest that metformin plus propranolol combined treatment might be beneficial for triple negative breast cancer control, with no symptoms of toxicity.